Cover Image

Challenges and controversies in resectable non-small cell lung cancer: a clinician’s perspective

The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is transforming due to the approval of novel adjuvant and neoadjuvant systemic treatments. The European Medicines Agency (EMA) recently approved adjuvant osimertinib, adjuvant atezolizumab, adjuvant pembrolizumab, a...

Full description

Saved in:
Bibliographic Details
Main Authors: Houda, Ilias (Author) , Dickhoff, Chris (Author) , Uyl-de Groot, Carin A. (Author) , Damhuis, Ronald A. M. (Author) , Reguart, Noemi (Author) , Provencio, Mariano (Author) , Levy, Antonin (Author) , Dziadziuszko, Rafal (Author) , Pompili, Cecilia (Author) , Di Maio, Massimo (Author) , Thomas, Michael (Author) , Brunelli, Alessandro (Author) , Popat, Sanjay (Author) , Senan, Suresh (Author) , Bahce, Idris (Author)
Format: Article (Journal)
Language:English
Published: March 2024
Series:Advancements in non-small cell lung cancer
In: The lancet. Regional health
Year: 2024, Volume: 38, Pages: 1-8
ISSN:2666-7762
DOI:10.1016/j.lanepe.2024.100841
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.lanepe.2024.100841
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2666776224000073
Get full text
Author Notes:Ilias Houda, Chris Dickhoff, Carin A. Uyl-de Groot, Ronald A. M. Damhuis, Noemi Reguart, Mariano Provencio, Antonin Levy, Rafal Dziadziuszko, Cecilia Pompili, Massimo Di Maio, Michael Thomas, Alessandro Brunelli, Sanjay Popat, Suresh Senan, and Idris Bahce
Description
Summary:The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is transforming due to the approval of novel adjuvant and neoadjuvant systemic treatments. The European Medicines Agency (EMA) recently approved adjuvant osimertinib, adjuvant atezolizumab, adjuvant pembrolizumab, and neoadjuvant nivolumab combined with chemotherapy, and the approval of other agents or new indications may follow soon. Despite encouraging results, many unaddressed questions remain. Moreover, the transformed treatment paradigm in resectable NSCLC can pose major challenges to healthcare systems and magnify existing disparities in care as differences in reimbursement may vary across different European countries. This Viewpoint discusses the challenges and controversies in resectable early-stage NSCLC and how existing inequalities in access to these treatments could be addressed.
Item Description:Gesehen am 30.10.2024
Physical Description:Online Resource
ISSN:2666-7762
DOI:10.1016/j.lanepe.2024.100841

Similar Items